Can G8 Scoring in Patients with Geriatric Lung Cancer Help to Determine Curative Treatment?

Main Article Content

Şule Karabulut Gül
Hüseyin Tepetam


Objective: The median age at diagnosis of lung cancer is 70 years and there are limited data in the literature regarding the treatment of elderly patients. In elderly patients, comorbid diseases, poor performance, and toxicity may lead to a surge in physicians' curative treatment and may remain untreated. The aim of this study was to evaluate the results of treatment in patients older than 70 years whose performances were evaluated by using Geriatric 8 score and to find out the response to curative treatment.

Materials and Methods: 124 patients over 70 years of age were evaluated retrospectively. 68 patients with early stage or locally advanced non-small cell lung cancer who were inoperable but not suitable for stereotactic radiotherapy were evaluated retrospectively. Geriatric 8 (G8) screening test was used to identify elderly cancer patients who could benefit from curative treatment. Patients received curative chemoradiotherapy or radiotherapy alone.

Results: In all patients (68), overall survival (83% for 1 year, 66% for 2 years) was median 18 months and disease free survival (58% for 1 year, 34.1% for 2 years) was median 14 months. As the G8 score increased, a statistically significant increase was observed in overall and disease free survival. Having weight loss or not, presence of accompanying disease, having good or bad health situation, having body mass index above and below 21, and the usage number of medications below or above 3 affects overall and disease free survival. When only the patients who received radiochemotherapy (n = 43) were evaluated, the mean survival (free of the ECOG performance score) was 12.8 months with G8 score less than 14 and 29.17 months with G8 score 14 and above and were statistically significant (p = 0.000).

Conclusion: When making a treatment decision, clinical evaluation should be performed well in patients older than 70 years with non-small cell lung cancer (NSCLC). In our study, overall survival and disease free survival were found to be better in patients with a G8 score above 14. Therefore, we think that it may be appropriate to use curative concurrent radio chemotherapy in selected patients with high G8 score and not to decide on biological age in elderly patients.

G8 scoring, lung cancer, body mass index, radio chemotherapy.

Article Details

How to Cite
Karabulut Gül, Şule, & Tepetam, H. (2020). Can G8 Scoring in Patients with Geriatric Lung Cancer Help to Determine Curative Treatment?. Journal of Cancer and Tumor International, 9(4), 1-7.
Original Research Article


Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136(5):359-86.

Siegel R, Naishadham D, Jemal A. Cancer statistics, CA Cancer J Clin. 2013;63(1): 11-30.

Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001;2(9):533-43.

Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010;303(11):1070-6.

Farray D, Mirkovic N, Albain KS. Multimodality therapy for stage III non-smallcell lung cancer. J Clin Oncol. 2005; 23:3257-69.

Belderbos J, Uitterhoeve L, van Zandwijk N, et al. Randomised trial of sequential versus concurrent chemoradiotherapy in patients with inoperable non-small cell lung cancer. Eur J Cancer. 2007;43:114-21.

Curran WJ, Scott CB, Langer CJ, et al. Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 94-10. Proc Am Soc Clin Oncol. 2003;22:621.

Pallis AG, Gridelli C, Wedding U, et al. Management of elderly patients with NSCLC; updated expert’s opinion paper: EORTC Elderly Task Force, Lung Cancer Group and International Society for Geriatric Oncology. Ann Oncol. 2014;25: 1270-83.

Blanchard EM, Moon J, Hesketh PJ, et al. Comparison of Platinum-Based Chemotherapy in Patients Older and Younger than 70 Years, An Analysis of Southwest Oncology Group Trials 9308 and 9509. Journal of Thoracic Oncology. 2011;6(1):115-20.

Bellera CA, Rainfray M, Mathoulin-Pélissier S, Mertens C, Delva F, Fonck MPL. Screening older cancer patients: First evaluation of the G-8 geriatric screening tool. Soubeyran Annals of Oncology. 2012;23(8):2166-72.

Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001;2:533- 43.

Turkish Thoracic Society Lung and Pleural Malignancies Working Group. The relationship between risk factors and histological type in lung cancer. 11th Annual Congress of Turkish Thoracic Society. Antalya Turkey; 2008.

Owonikoko TK, Ragin CC, Belani CP, Oton AB, Gooding WE, Taioli E, et al. Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J Clin Oncol. 2007;25: 5570-7.

Alberg AJ, Brock MV, Ford JG, Samet JM, Spivack SD. Epidemiology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143(Suppl5):1-29.

Özgün MA, Karagöz B, Bilgi O, Kandemir GE, Türken O. The prognostic significance of comorbidity in non-small cell lung cancer and its relationship with other prognostic factors. UHOD. 2009;2:63-8.

Weiss J, Langer C. NSCLC in the elderly-the legacy of therapeutic neglect. Curr Treat Options Oncol. 2009;10(3-4):180-94.

Yu HM, Liu YF, Yu JM, Liu J, Zhao Y, Hou M. Involved-field radiotherapy is effective for patients 70 years old or more with early stage non-small cell lung cancer. Radiother Oncol. 2008;87(1):29-34.
(PMID: 18237795)

Atagi S, Kawahara M, Yokoyama A, Okamoto H, Yamamoto N, Ohe Y et al. Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-lung cancer; a randomized, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301). Lancet Oncol . 2012;13(7):671-8.